top of page
Image by Joshua Rodriguez

Immunology

Our immunology research is dedicated to addressing diseases caused by immune system dysfunction — including autoimmune and inflammatory disorders that affect hundreds of millions worldwide. It is estimated that approximately 600‑800 million people globally live with autoimmune condition

Our immunology research efforts

We focus on uncovering new therapeutic targets and pathways across both common and rare immune‑mediated diseases. Some of the most frequently diagnosed immune challenge diseases include rheumatoid arthritis, psoriasis, type 1 diabetes, and lupus. NCBI +1 Our work bridges discovery research, translational science, and clinical development to bring promising therapies to patients more efficiently.

Exploring new modalities

To meet the demands of complex immune disorders, we leverage advanced therapeutic modalities such as biologics, cell therapies, and precision‑targeted interventions. These novel approaches aim to bring durable responses and better long‑term outcomes where traditional treatments may fall short.

Bringing precision medicine to immunology

We’ve made significant investments over the past few year and hope to usher in a new era in immunology. We're pursuing biomarkers that could play a key role in identifying people who are more likely to respond to therapies. The ultimate goal is to be able to deliver the right medicine for the right patient at the right time.

Innovation strengths

Across disease areas and development stages, we follow 3 tenets to drive innovation forward.

Genventislab.png

Our focus on immunology research interest & treatments

We’re building on our deep expertise and historic legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process, and offer solutions for more diverse patient populations. Our advanced technologies support a rich pipeline of medicines for some of the most challenging immunological diseases. Research interests include:

Understanding drivers of disease

Increasing understanding of disease through molecular profiling of patient samples, exploring preclinical disease to post-treatment states and using multi-omics, machine learning and artificial intelligence.

Fit for purpose drug discovery

Redesigning drug discovery using molecular profiles that reveal the genetic makeup of disease rather than diagnoses that describe disease.

Increasing probability of success in drug discovery

Developing more humanized preclinical model systems (e.g., CRISPR, iPSC, organoids and disease-on-a-chip) and state-of-the-art immunological, imaging and computational approaches to drive innovation of target identification, validation, benchmarking and prioritization.

Inducing of immune tolerance

Pursuing the biology behind inducing tolerance rather than suppressing pathological immune activity.

Drug delivery platforms

Investing in targeted drug delivery platforms, which are designed to specifically deliver a potent drug to the right cells and/or tissues. These include bispecifics, Antibody-Drug Conjugate platforms, small molecule approaches, RNA therapeutics and in situ cell reprogramming.

Related links

Image by Iván Díaz

Vaccines

We’ve been discovering, developing, supplying and delivering vaccines to help prevent disease for over 130 years.

Image by National Cancer Institute

Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.

OIP.jpg

Our science-led strategy is key to delivering long-term value for patients, employees, and shareholders.

bottom of page